antifungal + Lactobacillus vaginal spray

Lincoln Pharmaceuticals is developing a novel liquid vaginal spray that combines an unspecified antifungal small molecule with *Lactobacillus*, a live biotherapeutic. This combination therapy is designed to treat vaginal fungal infections, such as vulvovaginal candidiasis, while simultaneously addressing vaginal dysbiosis. The antifungal component targets and eliminates fungal pathogens, while the *Lactobacillus* probiotic works to restore the natural balance of the vaginal microbiota, potentially preventing the recurrence of infections. This product is part of Lincoln Pharmaceuticals' portfolio of innovative drug delivery formulations and is currently listed as a patented innovation in their research and development pipeline.

Other names

Novel liquid vaginal spray with antifungal agent and lactobacillusvaginal spray (antifungal + probiotic)